Nothing said here yet.
to join the conversation.
Prime Medicine, Inc. (PRME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PRME shares jump nearly 26% in a month as FDA clearance for PM647 and PM577a's clinical debut advances its gene-editing pipeline.
-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation in ATP7B, the most prevalent Wilson disease-causing…
Investing.com -- Prime Medicine Inc (NASDAQ:PRME) shares gained over 12% in after-hours trading Thursday following the FDA's clearance of the company's Investigational New Drug application for PM647, an in vivo gene editing therapy for Alpha-1 Antitrypsin…
-- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory clearances for PM577a -- -- Initial clinical data expected in 2027 --
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc.
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of 0.00% and -73.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 -- -- Favorable arbitration resolution with Beam…
Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.